|
Stereotactic body radiotherapy boost toxicity for high and intermediate-risk prostate cancer: Report of a multi-institutional study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Genesis Cancer Care |
Consulting or Advisory Role - Janssen |
Research Funding - Mundipharma |
|
|
Stock and Other Ownership Interests - GenesisCare |
|
|
|
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - UpToDAte is an online continuing education Journal - I wrote a Chapter and receive Royalties |
Travel, Accommodations, Expenses - Accuray |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |